• The NHI medical fee schedule is the reimbursement method for all healthcare services in Japan and is revised every two years. The reimbursement is set by points (one point is 10 yen).
• Japan being a low generic adoption market, one critical cost-containment measure was to increase generic uptake to generate savings to fund innovative medicines and control the health care expenditure.
• The Ministry of Finance predicted that if the generic penetration increased from 60% to 80%, 700 billion yen (5.2 billion euro) could be saved by 2020.
OBJECTIVES
• The objective of this research was to provide an overview of policies implemented in Japan and the revision of the NHI medical fee schedule to boost generics uptake, and to assess the impact of these measures.
METHODS
• Information on generics uptake and policies were retrieved from the Japanese authority website, Japan Generic Medicines Association website and grey literature. The revisions of the NHI medical fee schedule which encourage generic uptake were identified from the NHI medical fee schedule list.
• Rates of generics penetration were presented in terms of both old indicator and new indicator  The old indicator is defined as the generics' share of the total pharmaceutical market.  The new Indicator is defined as the generics' share of the off-patent market.
RESULTS
Overview of health policies to boost generic uptake:
• Generics health policies have been implemented in Japan since 2002.
 National Health Insurance (NHI) medical fee schedule introduced financial incentives to prescribe generic drugs for medical service providers in 2002. (Table 1 ). Since then, various financial incentives to promote generic use by medical services providers have been implemented in the revision of the NHI medical fee schedule by changing reimbursement points of healthcare services as described in Table 1 . A new indicator was introduced to achieve a generic uptake rate that is comparable internationally.
 In 2014, more aggressive financial incentives in the NHI's medical fee schedule were introduced, setting up a generic volume threshold for pharmacies. In addition, a financial incentive was introduced to the DPC system by creating a threshold for generics use that is over 60%. (Table 1)  In 2015, the target year defined in the roadmap 2013 was changed to the end of fiscal year 2016 by the council on Economic and Fiscal Policy to accelerate the generic penetration rate [2] .
Assessment of the impact of measures:
• The recent policies allowed a fast uptake of generics in Japan, especially in the recent years.
• The generic market share continuously increased from 32.5% ( [3, 4] . (Figure 1) • Generic penetration increased by 7.0% between September 2011 and September 2013 while increase was by 2.4% between September 2005 and September 2007 3, 4 . Generic uptake increased by 4.4% between 2013 and 2014 [3, 4] . (Figure 1 )
CONCLUSIONS
• The recent health policy measures to increase generics penetration confirm this as a priority for policy decision makers in Japan. Following recent aggressive policies, the Japanese generic market will soon match other developed countries.  Adding extra points (2 points) when generics were prescribed at medical institutions (inpatient and outpatient) and at pharmacies by a pharmacist.  Adding extra points (10 points) when pharmacists filled a prescription of generics after consultation with a patient.
2003
• Diagnostic procedure combination (DPC) was started
2006
• Revision of the NHI medical fee schedule
• Prescription format was revised adding a check mark " OK for change to a generic" on a prescription form to make the prescription of generics easier.
• Financial incentives to pharmacists was introduced adding points (10 points) when patients changed their branded drug to the generic on pharmacist's advice.
2007
• Basic Policy for Economic and Financial Reform: the proportion (volume) of generics penetration over 30% (old indicator) by 2012
• Action program for promoting generics by stable distribution, good quality, and providing generics information.
2008
• Prescription form was revised to include a physician's signature/stamp on the form for when a branded drug should be prescribed. Without the physician's signature/stamp, a pharmacy may allow the changing of a branded drug to a generic by patient's choice.
• Financial incentive to pharmacies was introduced adding extra points (4 points) into prescription fees when the proportion (volume) of generic prescription is over 30% at a pharmacy
2010
• Financial incentive to pharmacies based on the proportion (volume) of generic prescription was revised:
 If the proportion (volume) of generics at a pharmacy is over 20%  6 additional points  Over 25%  13 additional points  Over 30%  17 additional points
• Financial incentive to medical institutions based on the proportion (volume) of generics prescription was introduced:
 If the proportion (volume) of generics at a medical institution is over 20%  30 additional points (for inpatients excluding DPC).
• Prescription rule was changed allowing changes of dosage forms (e.g. one 10mg tablet  two 5mg tablets) making a change easier to generics from branded drugs when the same dosage was not available.
2012
• Financial incentive to pharmacies based on the proportion (volume) of generic prescription was revised as follows:
 The proportion (volume) of generics at a pharmacy is over 22%  5 additional points  Over 30%  15 additional points  Over 35%  19 additional points
• Financial incentive to medical institutions based on the proportion (volume) of generics prescription was revised:
 If the proportion (volume) of generics at a medical institution is over 20%  28 additional points (for inpatients excluding DPC ).  Over 30%  35 additional points (for inpatients excluding DPC)
• Prescription form was modified to allow changes to generics by each drug name which was used as a prescription base (if physician checked "no change to generics" on a prescription, it was not possible to change branded drugs to generics).
• Financial incentive to physicians was introduced adding extra points (2 points) when physicians prescribe at least one INN name on a prescription form.
• Financial incentive to pharmacists was revised increasing to 41 points (by 11) from 30 points, for giving information on generic drug usage, for prescribed drugs ( Generics on market or not, price of generics, and the stock status of generics) Overview of generics policy and penetration in Japan
